Fresh analysis suggests that individuals who stop using new slimming jabs like Wegovy and Mounjaro may regain shed pounds far faster than those who halt traditional lifestyle regimens.
Published data in a leading health publication demonstrates that while obese people can lose substantial amounts of their total mass while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing such medications must be informed of the risk of quick weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a return to original mass in about one and a half years.
Comparing Treatments
The research, which reviewed 37 of studies involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
Scientists emphasize that people who shed pounds through lifestyle changes alone generally have a more gradual weight regain—approximately 100 grams monthly—after stopping.
Explaining the Rapid Regain
Experts believe the mechanism of the jabs explains the amplified regain.
These medications imitate a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication results in hunger is unsuppressed, making overeating far more likely."
A Lifelong Issue?
The NHS advise the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, considering the high risk of weight regain, the therapy is often long-term.
This view is echoed by drug manufacturers, who note that the findings "highlight the persistent character of excess weight," akin to managing diseases like hypertension.
User Accounts
Users who have come off the jabs describe a sudden return of appetite.
"It felt as if something that goes on and you're instantly starving," said an individual.
This difficulty is compounded if individuals have not adopted sustainable dietary or behavioural modifications during treatment.
Significant Adoption
Figures show that millions of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is greater among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent solution and maintained weight loss hinges on ongoing lifestyle management.